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(n = 12, 30 %). the most common grade 3/4 adverse events 
were neutropenia (n = 7, 16 %) and pneumonia (n = 5, 
12 %). two patients died of pneumonia and dyspnea.
Conclusions Crel-free paclitaxel in combination with 
gemcitabine demonstrated favorable antitumor activity with 
little emetogenicities in non-small cell lung cancer patients. 
However, frequent grade 3/4 toxicities were observed, and 
safety should be evaluated thoroughly in future studies.
Keywords non-small cell lung cancer · gemcitabine · 
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Introduction
lung cancer is the most common cause of cancer mortal-
ity, and most patients are diagnosed at inoperable advanced 
stages [1]. In inoperable non-small cell lung cancer, plat-
inum-based doublet chemotherapy is widely accepted 
as the first-line palliative chemotherapy as it is beneficial 
to overall survival and quality of life. In the early 2000s, 
both cisplatin and carboplatin were comparably effec-
tive platinum-based regimens when combined with newer 
chemotherapeutic agents, such as paclitaxel, docetaxel, or 
gemcitabine [2]. However, platinum’s characteristic side 
effects including nephrotoxicity and neurotoxicity limit 
its administration. Based on these considerations, several 
studies [3–8] reported the results of combination cytotoxic 
chemotherapy without platinum agents for non-small cell 
lung cancer. In previous phase III trials [4, 6], paclitaxel 
200 mg/m2 and gemcitabine 1,000 mg/m2 on days 1 and 
8 (Pg) combination as first palliative chemotherapy had 
anticancer activity and tolerability similar to carboplatin at 
an area under the time concentration curve (aUC) of 6 mg 
and paclitaxel 200 mg/m2, and similar activity and better 
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myelotoxicity than carboplatin at aUC of 6 mg and gemcit-
abine 1,000 mg/m2 on days 1 and 8. Compared with these 
two cisplatin-based regimens, Pg combination chemother-
apy had similar overall survival and quality of life [8].
Paclitaxel is one of the most commonly used cytotoxic 
anticancer agents in combination with platinum and pos-
sesses anticancer activity as a non-platinum doublet Pg 
regimen. two major concerns of paclitaxel administration 
are hypersensitivity reactions and neurotoxicity. Because 
of paclitaxel’s water insolubility, Cremorphor el (Crel) 
is used as a formulation vehicle, although it has toxic 
effects such as severe anaphylactoid hypersensitivity reac-
tions, hyperlipidemia, and peripheral neuropathy [9]. to 
avoid these drawbacks, novel Crel-free formulations are 
of interest. genexol-PM (Samyang Co., Seoul, Korea) is a 
novel formulation of Crel-free, polymeric micelle formu-
lation of paclitaxel. In a phase I study [10], genexol-PM 
had a maximum tolerated dose of 390 mg/m2/3 weeks, 
higher than that of paclitaxel (175 mg/m2/3 weeks). neu-
tropenia, myalgia, and neuropathy were dose-limiting tox-
icities. In a phase II trial [11] for non-small cell lung can-
cer patients, genexol-PM dose ranging 230–300 mg/m2/3 
weeks in combination with cisplatin was generally well 
tolerated and showed significant anticancer activity (overall 
response rate 37.7 %). the efficacy and tolerability of gen-
exol-PM as a non-platinum doublet for non-small cell lung 
cancer patients have not been studied. given the concerns 
of platinum side effects and relatively good tolerability of 
genexol-PM at higher doses, we designed a phase II study 
to assess the efficacy and safety of non-platinum doublet of 
genexol-PM in combination with gemcitabine in advanced 
non-small cell lung cancer patients.
Methods
Patients
eligibility criteria included a histologically confirmed diag-
nosis of advanced non-small cell lung cancer of aJCC 6th 
stage IIIB and IV. In recurrent cases after curative surgery, a 
6-month period after completion of adjuvant chemotherapy 
was required. no prior chemotherapy or radiotherapy was 
allowed except for whole brain radiotherapy. Patients were 
required to be of age ≥18-year old and to have eastern Coop-
erative Oncology group Performance Status of 0–2, at least 
one measurable lesion, life expectancy more than 3 months, 
and adequate bone marrow, liver, and renal function. Patients 
with uncontrolled symptomatic brain metastases were 
excluded. Written informed consent was obtained from every 
patient. this study was approved by the Institutional review 
Board at gachon University gil Medical Center and was 
registered in clinicaltrials.gov (nCt01770795).
Study design, treatment and assessment
this was a prospective, single-arm, single-center phase II 
study. the primary endpoint was an objective response rate 
assessed by reCISt version 1.0. the secondary endpoints 
were progression-free survival, overall survival, and safety 
profiles.
On day 1, genexol-PM 230 mg/m2 diluted in 500 ml 
of normal saline or 5 % dextrose water was intravenously 
infused over 3 h. gemcitabine 1,000 mg/m2 was intrave-
nously administered on days 1 and 8. Premedication with 
antihistamine and steroid was administered as needed. 
Chemotherapy was repeated with 3-week cycles until com-
pletion of intended six cycles, disease progression, consent 
withdrawal of participant, or occurrence of unacceptable 
toxicities. When dose reduction was required, study drugs 
were reduced by 25 %. With grade 3 peripheral neuropathy, 
genexol-PM was withheld until the neuropathy recovered to 
≤grade 2 and was reduced by 25 % when readministered.
responses were assessed by contrast-enhanced com-
puted tomography scans of chest and abdomen every 
6 weeks during the study drug administration, 3 weeks 
after the completion or withdrawal of study drugs, and 
every 8 weeks thereafter. Patients were observed until death 
or study closure. toxicities were assessed according to the 
nCI CtCae v3.0.
Statistics
according to Simon’s minimax phase II trial design, to 
test a null hypothesis with a response rate of 25 % and 
an alternative of 45 % at α = 5 % and power of 80 %, 41 
patients were needed. Forty-five patients were planned 
to be accrued to allow for a 10 % drop-out rate. Progres-
sion-free survival and overall survival were estimated by 
Kaplan–Meier method. Progression-free survival was cal-
culated from the date of the study drug initiation to the date 
of documented progression, the last exam, or death. Overall 
survival was estimated as the time from the date of the first 
administration of study drug to death or the date of the last 
follow-up visit.
Results
Patients and treatment outcome
Between January 2011 and august 2012, 45 patients were 
enrolled in the study. Of the 45 patients, two patients with-
drew consent before study drug commencement and were 
excluded from final analysis. among the final 43 patients 
who received study treatment, 38 (88 %) were male. 
the study subjects had a median age of 65 years (range 
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36–82-year old). thirteen patients (30 %) were elderly 
patients over 70-year old. all patients had stage IV disease 
at the time of study enrollment. twenty-eight patients (65 %) 
had adenocarcinoma, eight patients (19 %) had squamous 
cell carcinoma, and the remaining seven patients had other 
histologic subtypes. all patients had metastatic disease at the 
time of study treatment. the result of egFr mutation analy-
sis was available in 26 patients. twenty-three patients had 
wild-type egFr and three patients had egFr mutation (two 
patients with deletion in exon 19 and one with insertion in 
exon 20). Patient characteristics are described in table 1.
the median cycle of treatment administration was 4 
(range 1–6). the mean dose intensity was 209 mg/m2/3 
weeks (90.9 % of preplanned 230 mg/m2/3 weeks) for gen-
exol-PM, and 1853 mg/m2/3 weeks (92.7 % of preplanned 
2,000 mg/m2/3 weeks) for gemcitabine. Sixteen patients 
(37.2 %) completed the planned six cycles of chemotherapy.
Of the 43 patients included in final analysis, treat-
ment response could be assessed in 36 patients. an over-
all response rate was 46.5 % (95 % CI 31.6–61.4) with 0 
Cr and 20 Prs. Stable disease (SD) was achieved in eight 
(18.6 %) patients (table 2). the reasons for early study 
discontinuation before the first response evaluation were 
loss to follow-up (n = 1), protocol deviation with palliative 
radiotherapy (n = 1), death (n = 2), and prolonged grade 
3 adverse events (n = 3). after a median follow-up dura-
tion of 18.6 months (range 3.0–27.5 months) for living 
patients, the median PFS was 4.0 months (95 % CI 2.4–
5.6 months). the median OS was 14.8 months (95 % CI 
3.6–25.9 months) (Fig. 1).
Safety
among 43 patients, the most common toxicity was ane-
mia (n = 29, 85 %) (table 3). the most common non-
hematologic toxic effects were asthenia (n = 17), myal-
gia (n = 16), peripheral neuropathy (n = 15), diarrhea 
(n = 12), dyspnea (n = 12), and anorexia (n = 11). nota-
bly, there was no grade 3–4 chemotherapy-induced nausea 
or vomiting, with only seven patients experiencing grade 
1–2 emesis. no hypersensitivity reaction was observed.
the grade 3–4 adverse events (ae) occurred in 22 
patients (51.2 %). the most common grade 3–4 hema-
tologic toxicity was neutropenia (n = 7) including four 
patients with neutropenic fever. the most common grade 
3–4 non-hematologic toxicities were pneumonia (n = 5), 
followed by asthenia (n = 3), pulmonary thromboembolism 
(n = 3), myalgia (n = 2), peripheral neuropathy (n = 2), 
diarrhea (n = 1), skin rash (n = 1), and dyspnea (n = 2). In 
nine patients, the study drug was discontinued because of 
toxicities. two patients died during the study period with-
out evidence of disease progression. One patient was found 
dead upon arrival at an emergency room from sudden dysp-
nea after 2 cycles of study drugs. the other patient was 
admitted to an intensive care unit (ICU) to manage grade 
4 pneumonia after the first cycle; he was dropped because 
of prolonged pneumonia treatment and eventually died of 
cerebral infarction while in the ICU.
Discussion
In this phase II study, Crel-free paclitaxel genexol-PM 
in combination with gemcitabine demonstrated significant 
Table 1  Patient baseline characteristics (n = 43)
* Deletion in exon 19 or l858r in exon 21







 Male 38 (88)
 Female 5 (12)
eCOg performance status
 0 22 (51)
 1 17 (40)
 2 4 (9)
Histology
 adenocarcinoma 28 (65)
 Squamous cell carcinoma 8 (19)
 Others 7 (16)
Smoking history
 Smoker 36 (84)
 never smoker 7 (16)
Previous radiotherapy to symptomatic brain metastases
 Yes 4 (9)
 no 39 (91)
egFr mutation
 Wild type 23 (53)
 Mutant* 3 (7)
 Unknown 17 (40)
Table 2  response according to reCISt (version 1.0)
response number of patients (95 % CI)
Complete response 0 (0 %)
Partial response 20 (46.5 %, 31.6–61.4)
Stable disease 8 (18.6 %, 7.0–30.2)
Progressive disease 8 (18.6 %, 7.0–30.2)
Withdrawal without evaluation 7 (16.3 %, 5.2–27.3)
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antitumor activity for advanced nSClC patients, with a 
partial response rate of 46.5 %. this is the first report of 
genexol-PM as a non-platinum combination for nSClC 
patients.
the non-platinum doublet of gemcitabine and taxane 
had similar anticancer activities and different toxicity 
profiles in lung cancer patients, compared with platinum 
doublet regimens [3, 6]. Paclitaxel and gemcitabine were 
compared with combinations of paclitaxel and carboplatin 
[4], gemcitabine and carboplatin [6], and paclitaxel and 
vinorelbine [5] in phase III trials. all of the studied regi-
mens possess similar antitumor efficacies, suggesting that 
the choice among these platinum and non-platinum combi-
nation depends on the toxicity profiles. the strengths of the 
non-platinum regimen lay in less frequent myelotoxicity 
and emetogenicity than a platinum-based doublet, apparent 
in the current study, too. this is consistent with the obser-
vation of a lower risk of neutropenia than Crel containing 
paclitaxel in phase I trials of genexol-PM [10, 12]. Consid-
ering that the elderly lung cancer patients often suffer from 
increased risk of myelotoxicity and renal toxicity from 
platinum-based doublet chemotherapy [13], the advantage 
of non-platinum combination can be further evaluated in 
this population. neurotoxicity may be a disadvantage of a 
non-platinum doublet regimen, as paclitaxel and gemcit-
abine had a significantly higher risk of peripheral neuro-
toxicities than gemcitabine and carboplatin [6]. However, 
in the present study with Crel-free paclitaxel formulation, 
higher doses of paclitaxel were well tolerated with similar 
risks of peripheral neurotoxicities, offering an alternative as 
a non-platinum doublet.
In line with previous trials of genexol-PM, our study 
demonstrated that genexol-PM enabled administration 
of higher doses of paclitaxel, as the mean dose inten-
sity of Cremorphor-free paclitaxel was 209 mg/m2/3 
weeks. although we cannot make a direct comparison, 
a study of conventional paclitaxel and gemcitabine for 
nSClC patients [6] showed similar adverse event rate of 
grade 3/4 neutropenia (18 %) and grade 3 peripheral neu-
ropathy (5 %) with a lower dose intensity of paclitaxel 
(median 170 mg/m2/3 weeks). another trial of paclitaxel 
and gemcitabine [5] demonstrated a similar dose intensity 
of paclitaxel and adverse events. In this study, despite the 
higher paclitaxel dose, the rates of grade 3/4 neutropenia 
and grade 3 peripheral neuropathy were 18 and 5 %. the 
Fig. 1  Survival graphs of the 
43 patients, a progression-free 
















































Table 3  Overview of adverse events
toxicity grade 1/2  
no. of patients (%)
grade 3/4  
no. of patients (%)
Hematologic
 anemia 29 (67) 0 (0)
 neutropenia 0 (0) 7 (16)
 thrombocytopenia 0 (0) 0 (0)
non-hematologic
 Skin rash 5 (12) 1 (3)
 Pruritus 2 (5) 0 (0)
 Hypersensitivity reaction 0 (0) 0 (0)
 Peripheral neuropathy 13 (30) 2 (5)
 Myalgia 14 (33) 2 (5)
 arthralgia 4 (9) 0 (0)
 asthenia 14 (33) 3 (7)
 anorexia 11 (26) 0 (0)
 nausea 4 (9) 0 (0)
 Vomiting 3 (7) 0 (0)
 Diarrhea 11 (26) 1 (3)
 Constipation 5 (12) 0 (0)
 left ventricular  
dysfunction
0 (0) 1 (3)
 Dyspnea 10 (23) 2 (5)
 Pulmonary  
thromboembolism
0 (0) 3 (7)
 Pneumonia 0 (0) 5 (12)
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overall response rate of this study (46.5 %) seems to be 
higher than 27.5 and 31 % observed previously [5, 6] with 
the same regimen of Crel-based paclitaxel, perhaps result-
ing from the higher dose intensity of paclitaxel.
the advantage of Crel-free paclitaxel over conven-
tional paclitaxel was expected to include delivery of higher 
doses and enhanced tumor distribution [10]. a tendency 
toward a higher response rate of this study might be related 
to the higher dose intensity. expected toxicities such as 
hematologic toxicity, peripheral neuropathy, and myalgia 
were favorable with higher doses of paclitaxel administra-
tion. Crel was thought to be related to the hypersensitiv-
ity reaction of paclitaxel; therefore, Crel-free paclitaxel 
formulation was expected not to produce hypersensitiv-
ity reactions. although no hypersensitivity reactions were 
observed in a phase I trial, subsequent phase II trials found 
significant risks of hypersensitivity reactions (seven among 
69 patients) or skin rash [11, 14, 15]. thus, a hypersensitiv-
ity reaction may be unavoidable with Crel-free formula-
tion. We observed no hypersensitivity reactions, although 
one patient experienced a grade 3 skin rash.
a platinum-based doublet regimen of genexol-PM for 
nSClC patients was studied in a phase II trial [11]. With 
higher median dose intensity of Crel-free paclitaxel 
(252 mg/m2/3 weeks) than that of this study, the response 
rate was comparable (37.7 %) to our study (46.5 %), 
although the rates of hematologic toxicities and periph-
eral neuropathy were higher with platinum-based doublet. 
Moreover, grade 2–4 nausea and vomiting were observed 
in about 30 % with genexol-PM and cisplatin, in contrast 
to 9 % with non-platinum doublet of this study.
grade 3/4 non-hematologic toxicities were frequent in 
this study; however, many of the study subjects had poor 
prognostic factors such as old age, male sex, or heavy 
smoking history, which might exaggerate the toxicity pro-
files. all the five events of grade 3–4 pneumonia were bac-
terial pneumonia, not drug-induced pneumonitis. the pos-
sibilities of toxicities from higher doses of paclitaxel itself 
cannot be completely excluded; therefore, we should be 
cautiously deliberate to balance the advantages of higher 
dose of paclitaxel with Crel-free formulation with the 
potential harm.
as egFr tyrosine kinase inhibitor (tKI) was estab-
lished as first-line treatment during study period, only 
three subjects with egFr mutation who could not afford 
to egFr tKI were included and egFr status of the most 
patients were wild type or unknown. a recent retrospective 
study [16] reported that egFr mutant patients had better 
PFS to taxane-including treatment than a gemcitabine-
based regimen. In our study, two patients with sensitive 
egFr mutations showed long PFS of 6 and 10 months.
In conclusion, genexol-PM with gemcitabine showed 
a comparable efficacy in nSClC patients with less 
myelotoxicity and emetogenicity. given the significant risk 
of grade 3/4 non-hematologic adverse events, clinicians 
should be cautious in selection of candidates and further 
evaluation.
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